Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 study of ulacamten (CK-4021586) in healthy adults
NCT05877053Phase 1Completed
- Sponsor
- Cytokinetics
- Start
- May 2023
- Primary completion
- Nov 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of ck-586 in heart failure with preserved ejection fraction (HFpEF) (5 arms), sponsored by Cytokinetics. Primary endpoint: Incidence and severity of Adverse Events. Started May 2023; status: completed.
02
Drugs
ck-586
03
Conditions
heart failure with preserved ejection fraction (HFpEF)
Beyond the preview
Go deeper on NCT05877053.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05877053.